The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Have we just hit another all time low?? This is madness
They need to let Allenby provide an update note regardless of how low the Oxilio deal figures may be. Its not a good look to not allow your broker to comment on a global licencing deal.
Need something to add value and generate interest here, they have decimated their own share price but as said before, it's all about the share of deals to them, the share price means absolutely nothing to them
Filter, I was kind of expecting NXP001 to 'add value and generate interest', I guess I was being too hopeful.
Yep, we've gone down instead, can't quite believe it, times like these I wish I knew how to trade. I just hope we start to see a rise in anticipation of the many bits of news due in Q4.
On the incentives side, its only Brindley who gets a share of a deal, which given it took 6 months for her to close out the Ox deal means she's not going to close out anything else.
Its just about data now.
Bring me the data!! What an absolute shambles we've witnessed here, surely the only way is up, said that at 3p though
"like these I wish I knew how to trade"
I wouldn't recommend trying to trade this share for a start. If you take a look at the 3 year chart you can clearly see a stark change where the Blackwell camp took over from Gooding.
Under Gooding the share price movements were volatile as speculation about project possibilities was fast and loose. DG told us everything. This was ideal for traders. The problem for long term investors was that the deals either evaporated or didn't materialise at all. Under Blackwell we moved to the other extreme. The release of price sensitive information became extremely guarded. When we did eventually get a deal across the line no one could value it, so it was ignored. The decline from July 2020 is comparatively smooth, very little volatilty. Quite dangerous to trade short term given the only option is to go long in a bearish trend, easy to get caught out. I don't think the spread-betting companies cover it anymore so you can't even trade it short that way.
As disappointing as it is to see the price go down again, I think it's a market thing rather than anything to do with this deal. It's a sea of red across the board today.
Unfortunately when the markets have a good day, NFX goes down and when the markets have a bad day, NFX goes down.
oh well... I'm just reminiscing about the time we were in talks with 'multiple' parties on NXP002. Happy days.
"Nuformix is putting in place the team and development partnerships to pursue this path for NXP002. Funds from the Placing will allow Nuformix to drive progress in this programme and support Nuformix's position in the Group's on-going discussions with multiple potential development partners in Asia and the US."
"Unfortunately when the markets have a good day, NFX goes down and when the markets have a bad day, NFX goes down."
I'm certainly not going to challenge that.
I've made a few Bob, not a lot, trading twice .
Have lost an awful lot more selling down my holding over the past few months. But glad I did looking how things have gone since.
I actually thought over the weekend about averaging down what's left first thing Monday thinking sentiment had changed to the positive. Glad I didn't.
Perhaps no substantial positive reaction sp wise after 002 results as people wait to see if it can be marketed
More of the same or taken out?
ATB
"Nuformix is putting in place the team and development partnerships to pursue this path for NXP002. Funds from the Placing will allow Nuformix to drive progress in this programme and support Nuformix's position in the Group's on-going discussions with multiple potential development partners in Asia and the US."
Completely slipped my mind that! It would have been a great question for the AGM!:
"Did you manage to assign any Business Development agents to discuss the potential for any positive outcome regarding the legacy discussions with the Asian partners?"
Perhaps they did. Perhaps that's exactly why none of them seem too alarmed by the current sp and lack of reaction to the Oxilio deal....I can still dream.
10 March
"NXP002 Asia discussions: The Board is disappointed that previous business development activities in Asia have not reached a positive conclusion. A new business development consultant has been engaged to assess the viability of legacy discussions coming to a successful conclusion in the near to medium term."
The problem is now with Riddells purchase last week. If anything positive had come of the 'business development' he could not have made his buy.
Does that still apply if a prospective deal was arranged based on the data results (which are currently unknown)?
I suppose it does really as he is aware of something that is not in the public domain.
Very sad if so because that means nothing is lined up as yet.
It could be done in an informal way. e.g. there had been talks that were left in a position of 'come back to us once you've got results', so not agreement in place other than the door is still open.
Ah soup I completely forgot about that too, would email but they wouldn't say
Wonder what happened to that twitter poster called Make England Great @NFXupupup, he had some great posts last year... there's been some great characters but for some reason they all disappear.
"@NFXupupup Jul 24
#nfx its lined up to close NXP002 shortly. You would never state progress into next trial without confirmation in house of a deal. It looks very much like all systems are go and the formalities of the deal closed imminently. "
To be fair soup, we've all called nfx wrong. Anyone with the luxury of hindsight can seem like a genius. If I'd known where we would be at this moment I would have sold years ago in profit or with less of a loss, I still have faith though but it's hardly done me any favors
Agree SSM, feels like we’ve been played by the pump and dump brigade over the year.
Certainly everyone who paid for the shares they hold is sitting on a loss right now.
(I say paid, as DG and JH didn’t so will still be in the blue on theirs)
Getting daily all time lows now, really is pathetic. I pray this stays above 1p I really do, how much is a clean cash shell these days?
Don't worry filter, someone keeps buying 2 quids worth at a time. That'll prop the sp up.
Q4 can't come soon enough
Q4, I'm hopeful that news on NXP004 will come in the near term, they've been underway with the further research since May.
" While there is literature data and preliminary preclinical data generated by the Company providing evidence for this drug's potential activity in fibrosis, it is the Company's strategy that in order to derive most value from the NXP004 asset, the opportunities in oncology should be exploited as a priority.
Should the further research be positive, there are two potential options for licensing the Company's IP to generate value from NXP004:
-- license to the originator of the marketed drug to potentially extend its patent protection, thus potentially adding significant value for the originator; or
-- license to generic companies to potentially allow commercialisation of a generic alternative to the marketed drug."